The daily business briefing: March 1, 2022

Pfizer vaccine proved less effective against Omicron infections among small children, Disney halts movie releases in Russia, and more

A child's post-vaccine bandage
A child's post-vaccine bandage
(Image credit: David Ryder/Getty Images)

1. Pfizer vaccine less effective against Omicron among small children

The Pfizer-BioNTech coronavirus vaccine is significantly less effective in preventing infection in children ages 5 to 11 than in adolescents and adults, although it still prevents severe illness, according to data collected by New York State health officials. The study found that vaccine effectiveness in preventing infection fell during the Omicron surge from 66 percent to 51 percent among children aged 12 to 17, and from 68 percent to 12 percent in children aged 5 to 11, who got a smaller dose. The results of the study, which was conducted during the wave driven by the Omicron variant, came as New York City prepares to lift its mask mandate in schools.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.